| scholarly article | Q13442814 |
| P50 | author | Harvey J. Alter | Q5677307 |
| P2860 | cites work | Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease | Q30439222 |
| Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial | Q33345486 | ||
| Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia | Q33371166 | ||
| The use of riboflavin for the inactivation of pathogens in blood products | Q34000406 | ||
| Transmission of human herpesvirus 8 by blood transfusion. | Q34569442 | ||
| Protecting the blood supply from emerging pathogens: the role of pathogen inactivation | Q36106339 | ||
| Managing threats rather than risks in blood transfusion: robust design for a complex system | Q36640500 | ||
| West Nile virus among blood donors in the United States, 2003 and 2004. | Q40502172 | ||
| Estimated risk of West Nile virus transmission through blood transfusion during an epidemic in Queens, New York City | Q40572754 | ||
| Serosurveys for West Nile virus infection--New York and Connecticut counties, 2000. | Q40607494 | ||
| Clinical Medical Research Award. Hepatitis C virus and eliminating post-transfusion hepatitis | Q43000382 | ||
| Transfusion-transmitted viral infections: building bridges to transfusion medicine to reduce risks and understand epidemiology and pathogenesis | Q46854672 | ||
| Multicenter comparison of serologic assays and estimation of human herpesvirus 8 seroprevalence among US blood donors | Q47688207 | ||
| Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services | Q48081521 | ||
| Trends in transfusion-associated acquired immune deficiency syndrome in the United States, 1982 through 1991 | Q64135631 | ||
| Flu | Q73308188 | ||
| P433 | issue | 2 | |
| P921 | main subject | precautionary principle | Q515255 |
| P304 | page(s) | 97-102 | |
| P577 | publication date | 2008-04-01 | |
| P1433 | published in | Transfusion Medicine Reviews | Q15758511 |
| P1476 | title | Pathogen reduction: a precautionary principle paradigm. | |
| P478 | volume | 22 |
| Q37776318 | A comparison of methods of pathogen inactivation of FFP |
| Q38052141 | A patient-oriented risk-benefit analysis of pathogen-inactivated blood components: application to apheresis platelets in the United States |
| Q39615231 | Addressing the risk of bacterial contamination of platelets within the United States: a history to help illuminate the future |
| Q37923144 | Blood cell salvage during cesarean delivery |
| Q37715077 | Blood still kills: six strategies to further reduce allogeneic blood transfusion-related mortality |
| Q94682899 | Contemporary resuscitation of hemorrhagic shock: What will the future hold? |
| Q42792674 | Development of the S-303 Pathogen Inactivation Technology for Red Blood Cell Concentrates |
| Q38109050 | From hepatic diseases and jaundice to viral hepatitis: the configuration of a kaleidoscope. |
| Q26741073 | Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical use |
| Q37127899 | High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection |
| Q90719621 | In vitro evaluation of pathogen inactivated platelet quality: An 8 year experience of routine use in Galicia, Spain |
| Q55005212 | Initial Results of a Prospective Study and Identification of New Strategies to Increase Traceability of Plasma-derived Medicines. |
| Q30448799 | Irradiation eradication and pathogen reduction. Ceasing cesium irradiation of blood products |
| Q46379566 | Paired analysis of plasma proteins and coagulant capacity after treatment with three methods of pathogen reduction. |
| Q35095646 | Pathogen Inactivation of Platelet and Plasma Blood Components for Transfusion Using the INTERCEPT Blood System™ |
| Q37903671 | Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV Light. |
| Q50437023 | Pathogen reduction for platelets: available techniques and recent developments |
| Q43215972 | Performance of a fully automated quantitative neopterin measurement assay in a routine voluntary blood donation setting |
| Q33384501 | Platelet transfusion: products, indications, dose, threshold and efficacy |
| Q46356432 | Preclinical pharmacokinetic and toxicology assessment of red blood cells prepared with S-303 pathogen inactivation treatment |
| Q83795700 | Protecting the blood supply from emerging pathogens: the role of pathogen inactivation |
| Q50791013 | Quality of proteins in riboflavin and UV light-treated FFP during 1 year of storage at -18°C. |
| Q46513449 | Reduced alloimmunization in mice following repeated transfusion with pathogen-reduced platelets |
| Q37209101 | Reduction of the risk of bacterial contamination of blood components through diversion of the first part of the donation of blood and blood components |
| Q40611312 | Risks associated with red blood cell transfusions: potential benefits from application of pathogen inactivation |
| Q50545205 | Symptomatic parvovirus B19 infection caused by blood component transfusion. |
| Q40330073 | The Precautionary Principle and the Tolerability of Blood Transfusion Risks |
| Q34133145 | Transfusion‐associated infections: 50 years of relentless challenges and remarkable progress |
| Q84623023 | [Expected limits (and possible consequences) of pathogen inactivation technology] |
| Q84480522 | [Pathogen inactivation in platelet concentrates: the French experience] |
| Q50540750 | [Photochemical inactivation of pathogens in platelets and plasma: five years of clinical use in routine and hemovigilance. Towards a change of paradigm in transfusion safety]. |
Search more.